Using the RETeval-DR Electroretinograph for Early Diabetic Retinopathy Screening

September 07, 2016 1 comment

Individuals with diabetes know that blindness is a condition that they must be on the lookout for. One of the most frequent causes of new blindness cases among adults between 20 and 74 years of age is diabetic retinopathy.

Who is affected?

Among type 1 diabetic patients in their puberty or within the first three to five years of having diabetes, vision-threatening diabetic retinopathy (VTDR) is still rare. However, during the next 2 decades of living with the disease, retinopathy will develop in nearly all type 1 diabetics.

On the other hand, retinopathy can develop in up to 21% of type 2 diabetics at the time of their first diagnosis, or it will develop to some degree over time.

Diabetic retinopathy can cause vision loss due to:

  • New proliferative diabetic retinopathy (PDR) blood cells distorting the retina and leading to tractional retinal detachment
  • Bleeding occurring in these new blood cells; preretinal or vitreous hemorrhage can complicate the condition
  • PDR-associated neovascular glaucoma

Preventative measures to consider

To avoid the risks of vision loss early on, diabetic patients are advised to undergo diabetic retinopathy screening. This procedure can be done with the help of the appropriate equipment, such as the Welch Allyn RETeval-DR Electroretinograph.

General practitioners and eye specialists can effectively improve the management of their patients with this helpful tool. The device measures the retina's electrical response to light stimulation; this electrical activity is then magnified and recorded as waves (using non-invasive RETeval-DR Sensor Strips comfortably placed below each of the patient's eyes). If the retinas are diseased, the signals will be slower and smaller in size than usual.

KEY FEATURES: RETEVAL DR - ELECTRORETINOGRAPH:

  1. It is a portable handheld device that can be used anywhere diabetic patients receive care, for their utmost convenience.
  2. Screening with the tool can be accomplished in no time — it only takes three minutes.
  3. Use of RETeval-DR does not require the patient's eyes to be dilated, thus ensuring the patient's comfort.
  4. There is no need for practitioners using the device to go through even minimal training or deliver interpretations.
  5. The device provides immediate results, which are also delivered in a PDF report.

With high accuracy and a low technical failure rate, the RETeval-DR Electroretinograph proves to be an essential device that eye experts and general practitioners can use to provide early screening procedures. Diabetic patients can thus avoid vision loss which could potentially negatively affect their way of life.

If you would like to find out more click RETeval DR or contact our team at sales@amamedicalproducts.com.au to arrange a product demonstration 

 

SHARE THIS:

 Facebook Twitter LinkedIn

  


1 Response

Tom Mitchell
Tom Mitchell

September 20, 2016

This is an amazing device. High Negative Predictive values and low Positive predictive Values will enable Diabetics at risk of Diabetic Retinopathy to be identified for earlier intervention and better outcomes.

Leave a comment

Comments will be approved before showing up.